Research in Training at the Biomedical Signal Processing and Interpretation (BIOSPIN) Research Group
RT-ML // Deadline: 31/07/2026
Search Results for:
Research Assistant at the Molecular and cellular Neurobiotechnology Research Group
RA-JR // Deadline: 26/07/2026
AGENZIA ANSA: Ripristinata la vista nei topi con un farmaco attivato dalla luce
Un farmaco attivato dalla luce ha ripristinato la vista nei topi: funziona come una sorta di ‘protesi molecolare’ che sostituisce i sensori della retina ormai degenerati a causa della malattia, riattivando il circuito che trasporta i segnali al cervello.
Postdoctoral researcher at the at the Biomimetic systems for cell engineering Group
PR-EM // Deadline: 26/07/2026
Predoctoral researcher at the Protein Phase Transitions in Health and Disease Research Group
PhD-BB // Deadline: 31/07/2026
EL MUNDO: “Prótesis molecular” para la retina dañada: crean fármacos activados por luz que restauran la visión en ratones ciegos
Un consorcio internacional liderado por el IBEC ha desarrollado unos compuestos inteligentes que imitan las células fotorreceptoras dañadas en algunas enfermedades degenerativas. El avance abre la puerta a futuros tratamientos no invasivos mediante colirios.
LA VOZ DE GALICIA: Un fármaco que se activa con la luz y se administra como un colirio devuelve la visión a ratones ciegos
Actúa como una prótesis moleculares sin necesidad de implantes, tal y como se ha probado en una investigación dirigida por el Instituto de Bioingeniería de Cataluña, que espera iniciar los ensayos clínicos en humanos en dos o cuatro años
IBEC-led consortium develops light-activated drugs that restore sight in blind mice
A consortium led by the Institute for Bioengineering of Catalonia (IBEC) developed this approach based on photopharmacology, a technique to reversibly control drug activity with light. The newly developed compounds, called prosthe6, mimic the function of photoreceptor cells, which degenerate in blinding diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). These photoswitchable molecules show preliminary safety profiles and represent potential drug candidates for restoring vision in patients with degenerative retinal diseases, without the need for genetic manipulation or implanted devices.
IBEC to participate in Flagship European Grant for the Physics of Living Matter
Xavier Trepat and his team at the Institute for Bioengineering of Catalonia (IBEC) are key partners in ALIVE: Active Living Matter — Information, Vitality, and Emergence, an international research programme selected for funding through the first European edition of the Novo Nordisk Foundation Challenge Programme. Coordinated by the Niels Bohr Institute in Copenhagen, the project will receive 75 million DKK (around €10 million) over six years to uncover how information flows drive the emergence, organisation and function of living tissues.